Product Information
DEXTROAMPH-AMPHET ER 25 MG CAP is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $7.9239 per EA under NDC 00480368401. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Jan 31, 2022. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
DEXTROAMPH-AMPHET ER 25 MG CAP
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfateStrength
6.25; 6.25; 6.25; 6.25 mg/1; mg/1; mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480368401
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA210876FDA Approved
1/31/2022
TE Code
AB2
On Market Since
10/10/2023
Pharmacological Classes
Price Statistics
The NADAC for DEXTROAMPH-AMPHET ER 25 MG CAP has been published 129 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.9239 per EA |
|---|---|
| All-time high | $8.7095 (Aug 13, 2025) |
| All-time low | $7.8135 (May 22, 2024) |
| 52-week high | $8.5858 |
| 52-week low | $7.9239 |
| Median price | $8.3378 |
| Average price | $8.3210 |
| Largest weekly change | +6.0% (Jun 19, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEXTROAMPH-AMPHET ER 25 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for DEXTROAMPH-AMPHET ER 25 MG CAP, manufactured by Teva Pharmaceuticals USA Inc., is $7.9239 per EA (NDC 00480368401), effective Sep 30, 2026.
How has the price of DEXTROAMPH-AMPHET ER 25 MG CAP changed over time?
Over the history we have for it, the NADAC for DEXTROAMPH-AMPHET ER 25 MG CAP has held within roughly two percent of its current level. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for DEXTROAMPH-AMPHET ER 25 MG CAP?
Since Apr 17, 2024, the NADAC for DEXTROAMPH-AMPHET ER 25 MG CAP has ranged from a low of $7.8135 (May 22, 2024) to a high of $8.7095 (Aug 13, 2025), with a median of $8.3378 per EA.
Are there cheaper alternatives to DEXTROAMPH-AMPHET ER 25 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of DEXTROAMPH-AMPHET ER 25 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DEXTROAMPH-AMPHET ER 25 MG CAP?
DEXTROAMPH-AMPHET ER 25 MG CAP (NDC 00480368401) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.